DrugDrug NameDrug Indication
DB00364SucralfateThe sucralfate suspension [FDA label] and tablet [F4534] are used for the treatment of active duodenal ulcer for up to 8 weeks. The tablet form may be used at a lower dose for healed duodenal ulcers, for the purpose of maintaining healing and preventing recurrence [F4519, F4534]. Sucralfate is also used in the prevention and/or treatment of gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia [A177655, F4519].
DB01692DithioerythritolNot Available
DB01862Isopropyl beta-D-thiogalactopyranosideNot Available
DB04396ThiodigalactosideNot Available
DB15436GlucoraphaninNot Available